Nirmatrelvir and ritonavir treatment significantly reduces the risk of hospitalization and death from COVID-19 in high-risk individuals, according to a recent JAMA Network Open study. However, the treatment’s efficacy varied based on the degree of vulnerability, emphasizing tailored approaches for different risk groups.
Pharmalittle: We’re reading about Boehringer biosimilar frustrations, FTC warnings, and more
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal